IL-17RC Antibody (309822) [Alexa Fluor® 488]

PC-3 human prostate cancer cell line was stained with Mouse Anti-Human IL-17 RC Alexa Fluor® 488-conjugated Monoclonal Antibody (Catalog # FAB22691G, filled histogram) or isotype control antibody (Catalog # IC0041G, open histogram). View our protocol for Staining Membrane-associated Proteins.

• Reactivity: Hu
• Applications: Flow
• Clone: 309822
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 488

IL-17RC Antibody (309822) [Alexa Fluor® 488] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human IL‑17 RC
  Leu21-Ala454
  Accession # NP_116121
• Specificity: Detects human IL-17 RC in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) IL‑17 R, rhIL-17 BR, rhIL‑17 RD, or recombinant mouse IL-17 RC is observed.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: IL17RC
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 5 uL/10^6 cells

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied in a saline solution containing BSA and Sodium Azide.
• Preservative: Sodium Azide

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-17RC Antibody (309822) [Alexa Fluor® 488]

• FLJ95963
• FLJ96005
• IL-17 RC
• IL-17 receptor C
• IL-17 RL
• IL17F receptor
• IL17RC
• IL-17RC
• IL17Rhom
• IL17RL
• IL-17RL
• IL17-RL
• interleukin 17 receptor C
• interleukin-17 receptor C
• Interleukin-17 receptor homolog
• Interleukin-17 receptor-like protein
• MGC10763
• zcytoR14

Background

IL-17 Receptor C (IL-17 RC), also known as IL-17 RL and IL-17 Rhom, is an 85-110 kDa member of the IL-17 Receptor family. This is one of five families that currently comprise the cytokine receptor superfamily (1, 2, 3, 4, 5, 6). At this time, there are five members within the IL-17 receptor family, and these are termed IL-17 RA, B, C, D and E. Not all receptors appear to bind known members of the IL-17 cytokine family. To date, IL-17 RA is reported to bind IL-17(A), while IL-17 RB is reported to bind IL-17B and IL-17E (2, 4). Human IL-17 RC is a type I transmembrane glycoprotein that is expressed on a variety of nonhematopoietic cell types. These include endothelial cells (6, 7), chondrocytes and osteoblasts (8), breast and prostatic epithelium (6), and fibroblasts, plus renal tubular epithelium and skeletal muscle cells (8, 9). Full-length IL-17 RC is synthesized as a 791 amino acid (aa) precursor (10, 11). It contains a 20 aa signal sequence, a 518 aa extracellular domain (ECD) (aa 21‑538), a 21 aa transmembrane segment, and a 232 aa cytoplasmic region. Although IL-17 RA has two fibrinogen-like regions in its ECD that contribute to its function, no such architecture has been identified in the ECD of IL-17 RC (12). Based on studies looking at exon deletions, a key ligand-binding site would appear to exist over aa 425‑441 (13). The gene for human IL-17 RC contains 19 exons. It is estimated that there are over 90 alternative splice forms, with transmembrane-containing isoforms predominating (6, 14). The full-length isoform is estimated to occur approximately 10% of the time, while the three most common isoforms, as a group, occur about 50% of the time. Based on limited information, alternative splicing appears to regulate ligand specificity (13). R&D Systems IL-17 RC corresponds to IL-17 RC isoform # 3, which shows deletions of aa 36‑106 and 264‑278 relative to the full-length form (10). Over the ECD, IL-17 RC isoform #3 is 68% aa identical to mouse IL-17 RC ECD. IL-17 RC is the cognate receptor for IL-17F, and binds IL-17A with similar affinity (13). With IL-17 RA, it forms a definitive receptor for both IL-17A and IL-17F. The stoichiometry is unclear; it may form a heterodimer with IL-17 RA, or a heterotrimer with a preexisting IL-17 RA homodimer (4, 9, 13, 15). The heteromeric nature of the receptor may be important given that the predominant form of the IL-17 cytokine is now considered to be an IL-17A:IL-17F heterodimer (4).

1. Gaffen, S.L. et al. (2006) Vitam. Horm. 74:255.
2. Weaver, C.T. et al. (2007) Annu. Rev. Immunol. 25:821.
3. Moseley, T.A. et al. (2003) Cytokine Growth Factor Rev. 14:155.
4. Shen, F. and S.L. Gaffen (2008) Cytokine 41:92.
5. You, Z. et al. (2006) Cancer Res. 66:175.
6. You, Z. et al. (2007) Neoplasia 9:464.
7. Gerritsen, M.E. et al. (2003) Br. J. Pharmacol. 140:595.
8. Kokubu, T. et al. (2008) J. Histochem. Cytochem. 56:89.
9. Toy, D. et al. (2006) J. Immunol. 177:36.
10. GenBank Accession # Q96F46.
11. Haudenschild, D. et al. (2002) J. Biol. Chem. 277:4309.
12. Kramer, J.M. et al. (2007) J. Immunol. 179:6379.
13. Kuestner, R.E. et al. (2007) J. Immunol. 179:5462.
14. Haudenschild, D.R. et al. (2006) Prostate 66:1268.
15. Kramer, J.M. et al. (2006) J. Immunol. 176:711.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-17RC Antibody (FAB22691G)(1)

Publication using FAB22691G

• BRB Pires, R Binato, GM Ferreira, S Corrêa, B Du Rocher, D Bulzico, S Crocamo, EC Dos Santos, LG Lima, E Abdelhay Twist1 Influences the Expression of Leading Members of the IL-17 Signaling Pathway in HER2-Positive Breast Cancer Cells International Journal of Molecular Sciences, 2021-11-10;22(22):. 2021-11-10 [PMID: 34830027] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: IL17RC
• Uniprot:
  • NP_116121()